At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09688 ZAI LAB
Closed 04-23 16:08:12
17.220
-1.610
-8.55%
High17.980
Low17.110
Vol22.84M
Open17.980
D1 Closing18.830
Amplitude4.62%
Mkt Cap19.53B
Tradable Cap19.53B
Total Shares1.13B
T/O397.28M
T/O Rate2.01%
Tradable Shares1.13B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Zai Lab to Review and Publish Q1 2026 Results on 7 May; Earnings Call Scheduled Same Day
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer With Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Boehringer Ingelheim and Zai Lab Announce Collaboration on Dll3‑Targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.